KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Equity Average: 2011-2025

Historic Equity Average for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $99.8 million.

  • Rigel Pharmaceuticals' Equity Average rose 547.91% to $99.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.8 million, marking a year-over-year increase of 547.91%. This contributed to the annual value of -$12.7 million for FY2024, which is 40.00% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Equity Average stood at $99.8 million, which was up 98.55% from $50.3 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Equity Average's 5-year high stood at $99.8 million during Q3 2025, with a 5-year trough of -$30.8 million in Q2 2024.
  • Over the past 3 years, Rigel Pharmaceuticals' median Equity Average value was -$22.3 million (recorded in 2024), while the average stood at -$3.0 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Equity Average plummeted by 1,778.05% in 2023 and then skyrocketed by 547.91% in 2025.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Equity Average stood at $40.0 million in 2021, then crashed by 141.79% to -$16.7 million in 2022, then plummeted by 80.80% to -$30.2 million in 2023, then soared by 81.24% to -$5.7 million in 2024, then soared by 547.91% to $99.8 million in 2025.
  • Its last three reported values are $99.8 million in Q3 2025, $50.3 million for Q2 2025, and $10.9 million during Q1 2025.